DK1237930T3 - Kimære amyloid-beta-peptider - Google Patents
Kimære amyloid-beta-peptiderInfo
- Publication number
- DK1237930T3 DK1237930T3 DK00990195T DK00990195T DK1237930T3 DK 1237930 T3 DK1237930 T3 DK 1237930T3 DK 00990195 T DK00990195 T DK 00990195T DK 00990195 T DK00990195 T DK 00990195T DK 1237930 T3 DK1237930 T3 DK 1237930T3
- Authority
- DK
- Denmark
- Prior art keywords
- chimeric
- cleavage product
- precursor
- mature protein
- peptide cleavage
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 4
- 230000007030 peptide scission Effects 0.000 abstract 4
- 239000002243 precursor Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 230000003053 immunization Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16968799P | 1999-12-08 | 1999-12-08 | |
PCT/US2000/033203 WO2001042306A2 (en) | 1999-12-08 | 2000-12-08 | Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1237930T3 true DK1237930T3 (da) | 2007-03-19 |
Family
ID=22616757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00990195T DK1237930T3 (da) | 1999-12-08 | 2000-12-08 | Kimære amyloid-beta-peptider |
Country Status (15)
Country | Link |
---|---|
US (2) | US7901689B2 (da) |
EP (1) | EP1237930B1 (da) |
JP (1) | JP4804690B2 (da) |
CN (2) | CN1414976A (da) |
AT (1) | ATE344803T1 (da) |
AU (1) | AU784925B2 (da) |
CA (1) | CA2393763A1 (da) |
CY (1) | CY1108538T1 (da) |
DE (1) | DE60031792T2 (da) |
DK (1) | DK1237930T3 (da) |
ES (1) | ES2275570T3 (da) |
IL (2) | IL149976A0 (da) |
PT (1) | PT1237930E (da) |
WO (1) | WO2001042306A2 (da) |
ZA (1) | ZA200205032B (da) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2001042306A2 (en) * | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
ME00183B (me) * | 2000-02-21 | 2011-02-10 | Pharmexa As | Novi postupak za deregulaciju amiloida |
CZ20022748A3 (cs) | 2000-02-21 | 2004-03-17 | Pharmexa A/S | Nová metoda regulace obsahu amyloidu |
IL153943A0 (en) * | 2000-07-19 | 2003-07-31 | Upjohn Co | SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
AU2003279728B2 (en) * | 2002-10-01 | 2007-09-27 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
DE102006015001A1 (de) * | 2006-03-31 | 2007-10-11 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Verfahren zum Nachweis und/oder zur Anreicherung von Analytproteinen und/oder Analytpeptiden aus einer komplexen Proteinmischung |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
JP2009538924A (ja) | 2006-06-01 | 2009-11-12 | エラン ファーマシューティカルズ,インコーポレイテッド | Appの神経活性断片 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP1944314A1 (en) * | 2007-01-11 | 2008-07-16 | Philipps-Universität Marburg | Diagnosis of Alzheimer's disease and other neurodementing disorders |
WO2008084402A2 (en) | 2007-01-11 | 2008-07-17 | Philipps-Universitaet Marburg | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2182983B1 (en) | 2007-07-27 | 2014-05-21 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
EA026787B1 (ru) * | 2007-08-27 | 2017-05-31 | Общество С Ограниченной Ответственностью "Ниармедик Плюс" | Конструкция нуклеиновой кислоты и ее применение для лечения, предотвращения и сдерживания болезни альцгеймера |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
GB0812586D0 (en) * | 2008-07-09 | 2008-08-13 | Ucl Business Plc | Chimaeric peptide |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP2538982A4 (en) | 2010-02-25 | 2016-02-17 | Janssen Alzheimer Immunotherap | PET SURVEILLANCE OF IMMUNOTHERAPY DIRECTED AGAINST |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
WO2012123562A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Diagnostic antibody assay |
WO2014031697A2 (en) * | 2012-08-21 | 2014-02-27 | The Institute Of Molecular Medicine | COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN |
US9102752B2 (en) | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
WO2019044925A1 (ja) * | 2017-08-30 | 2019-03-07 | Kmバイオロジクス株式会社 | 改変型HSV gDタンパク質及びこれを含むワクチン |
CA3105706A1 (en) * | 2018-07-12 | 2020-01-16 | Hexamer Therapeutics Inc. | Self-assembling peptide scaffold |
JP2022528953A (ja) | 2019-04-05 | 2022-06-16 | タウク3 バイオロジクス リミテッド | 抗タウc3抗体及びその使用 |
WO2022235678A1 (en) * | 2021-05-03 | 2022-11-10 | Ohio State Innovation Foundation | Human anti-coronavirus peptide vaccines and methods of their use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018021A (en) * | 1994-10-19 | 2000-01-25 | The Research Foundation Of State University Of New York | Human transaldolase: an autoantigen with a function in metabolism |
AUPO390396A0 (en) * | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
NZ337765A (en) * | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2001042306A2 (en) * | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
-
2000
- 2000-12-08 WO PCT/US2000/033203 patent/WO2001042306A2/en active IP Right Grant
- 2000-12-08 CA CA002393763A patent/CA2393763A1/en not_active Abandoned
- 2000-12-08 AT AT00990195T patent/ATE344803T1/de active
- 2000-12-08 CN CN00818137A patent/CN1414976A/zh active Pending
- 2000-12-08 JP JP2001543601A patent/JP4804690B2/ja not_active Expired - Fee Related
- 2000-12-08 EP EP00990195A patent/EP1237930B1/en not_active Expired - Lifetime
- 2000-12-08 US US09/731,899 patent/US7901689B2/en not_active Expired - Fee Related
- 2000-12-08 AU AU27256/01A patent/AU784925B2/en not_active Ceased
- 2000-12-08 PT PT00990195T patent/PT1237930E/pt unknown
- 2000-12-08 ES ES00990195T patent/ES2275570T3/es not_active Expired - Lifetime
- 2000-12-08 CN CN2010101066741A patent/CN101935352A/zh active Pending
- 2000-12-08 DK DK00990195T patent/DK1237930T3/da active
- 2000-12-08 IL IL14997600A patent/IL149976A0/xx unknown
- 2000-12-08 DE DE60031792T patent/DE60031792T2/de not_active Expired - Lifetime
-
2002
- 2002-06-02 IL IL149976A patent/IL149976A/en not_active IP Right Cessation
- 2002-06-21 ZA ZA200205032A patent/ZA200205032B/en unknown
-
2007
- 2007-01-29 CY CY20071100123T patent/CY1108538T1/el unknown
-
2010
- 2010-11-22 US US12/951,836 patent/US20110280879A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2003516419A (ja) | 2003-05-13 |
US20110280879A1 (en) | 2011-11-17 |
AU2725601A (en) | 2001-06-18 |
ES2275570T3 (es) | 2007-06-16 |
EP1237930A2 (en) | 2002-09-11 |
EP1237930B1 (en) | 2006-11-08 |
ATE344803T1 (de) | 2006-11-15 |
CN1414976A (zh) | 2003-04-30 |
DE60031792D1 (de) | 2006-12-21 |
JP4804690B2 (ja) | 2011-11-02 |
PT1237930E (pt) | 2007-02-28 |
AU784925B2 (en) | 2006-07-27 |
WO2001042306A3 (en) | 2001-11-01 |
ZA200205032B (en) | 2003-09-22 |
CN101935352A (zh) | 2011-01-05 |
WO2001042306A2 (en) | 2001-06-14 |
US20060088548A1 (en) | 2006-04-27 |
IL149976A (en) | 2012-10-31 |
CY1108538T1 (el) | 2014-04-09 |
US7901689B2 (en) | 2011-03-08 |
IL149976A0 (en) | 2002-12-01 |
DE60031792T2 (de) | 2007-02-22 |
CA2393763A1 (en) | 2001-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1237930T3 (da) | Kimære amyloid-beta-peptider | |
CA2505250A1 (en) | Acetylated hmgb1 protein | |
EP3072522A1 (en) | Anti-kir combination treatments and methods | |
US9896514B2 (en) | Clostridium difficile antigens | |
AR018603A1 (es) | Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi | |
UA90846C2 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Ab) | |
NO335192B1 (no) | Immunologiske peptider og peptidpreparater som induserer dannelse av antistoffer som spesifikt bindes til et amyloid-beta-peptid; deres anvendelse til fremstilling av et medikament for behandling av et individ som lider av Alzheimers sykdom, og en fremgangsmåte for bestemmelse av hvorvidt en forbindelse er en inhibitor av amyloide avleiringer og fibrilldannelse. | |
NO20083805L (no) | Anvendelse av et antistoff som binder Aβ-peptidsekvenser | |
HUP0301723A2 (hu) | Eljárás peptidek előállítására in vitro transzkripciós/transzlációs rendszer alkalmazásával | |
DE69940775D1 (de) | Peptidzusammensetzung als immunogen zur allergiebehandlung. | |
BR0110927A (pt) | Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer | |
RU2013110876A (ru) | Активируемые биспецифические антитела | |
PE20050712A1 (es) | Anticuerpos rg1 | |
PE20091388A1 (es) | Moleculas y metodos para modular el componente de complemento | |
BR112020021111A2 (pt) | anticorpo multiespecífico, ácido nucleico e formulação farmacêutica | |
MX2021010404A (es) | Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas. | |
WO2014151747A1 (en) | Methods and compositions with immune therapy for treatment of dementia | |
MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
AU2002310474A1 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
Mruk et al. | Sertolin is a novel gene marker of cell-cell interactions in the rat testis | |
EP1752472A3 (en) | Chimeric amyloid beta peptides | |
ATE408631T1 (de) | Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion | |
DK1913020T3 (da) | Immunogene konstrukter | |
ATE75754T1 (de) | Monoklonale antikoerper gegen atriale, natriurethische peptide. | |
US10406197B2 (en) | Substances and methods for the use in prevention and/or treatment in Huntington's disease |